A proof of principle investigation of a novel enzyme formulation on dental calculus deposition: a 4-week randomized human clinical trial
Background The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics, Inc. has developed novel model of calculus development and structure and has formulated a dentifrice (Tartarase™) using digestive...
Gespeichert in:
| Veröffentlicht in: | BMC oral health Jg. 24; H. 1; S. 720 - 8 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
BioMed Central
22.06.2024
BioMed Central Ltd Springer Nature B.V BMC |
| Schlagworte: | |
| ISSN: | 1472-6831, 1472-6831 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics, Inc. has developed novel model of calculus development and structure and has formulated a dentifrice (Tartarase™) using digestive enzymes as active ingredients that is shown to dissolve dental calculus in this Proof of Principle clinical trial.
Methods
This investigation was designed to evaluate the safety and efficacy of a novel enzyme formulation to remove existing calculus deposits in 4 weeks, measured using the Volpe-Manhold Index (V-MI) on lingual surfaces of 6 lower anterior teeth. The test formulation was compared to Crest Cavity Protection, as a control dentifrice. A total of 40 randomized test subjects began the study with 20 assigned to the control dentifrice and 20 assigned to the Tartarase groups (ten each, one brushing with Tartarase twice daily and one brushed with Tartarase and wore a dental tray filled with Tartarase for 30 min then brushed again with Tartarase, once daily).
Results
The Crest group experienced a 12% increase in calculus, in contrast to the results of both Tartarase groups that experienced a 40% reduction in calculus in 4 weeks of unsupervised at home use of the Tartarase toothpaste formulation.
Conclusions
This proof of principle study demonstrates that a dentifrice, formulated along the lines of the Tartarase material, is capable of combating calculus accumulation using the same oral hygiene habits that are common worldwide.
Trial registration
This trial was registered retrospectively at clinicaltrials.gov and has the Unique Identification Number: NCT06139835, 14/11/2023. |
|---|---|
| AbstractList | Background The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics, Inc. has developed novel model of calculus development and structure and has formulated a dentifrice (Tartarase[TM]) using digestive enzymes as active ingredients that is shown to dissolve dental calculus in this Proof of Principle clinical trial. Methods This investigation was designed to evaluate the safety and efficacy of a novel enzyme formulation to remove existing calculus deposits in 4 weeks, measured using the Volpe-Manhold Index (V-MI) on lingual surfaces of 6 lower anterior teeth. The test formulation was compared to Crest Cavity Protection, as a control dentifrice. A total of 40 randomized test subjects began the study with 20 assigned to the control dentifrice and 20 assigned to the Tartarase groups (ten each, one brushing with Tartarase twice daily and one brushed with Tartarase and wore a dental tray filled with Tartarase for 30 min then brushed again with Tartarase, once daily). Results The Crest group experienced a 12% increase in calculus, in contrast to the results of both Tartarase groups that experienced a 40% reduction in calculus in 4 weeks of unsupervised at home use of the Tartarase toothpaste formulation. Conclusions This proof of principle study demonstrates that a dentifrice, formulated along the lines of the Tartarase material, is capable of combating calculus accumulation using the same oral hygiene habits that are common worldwide. Trial registration This trial was registered retrospectively at clinicaltrials.gov and has the Unique Identification Number: NCT06139835, 14/11/2023. Keywords: Calculus, Enzymes, Brushing, Volpe-Manhold Index (V-MI), Adverse, Safety, Formulation The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics, Inc. has developed novel model of calculus development and structure and has formulated a dentifrice (Tartarase[TM]) using digestive enzymes as active ingredients that is shown to dissolve dental calculus in this Proof of Principle clinical trial. This investigation was designed to evaluate the safety and efficacy of a novel enzyme formulation to remove existing calculus deposits in 4 weeks, measured using the Volpe-Manhold Index (V-MI) on lingual surfaces of 6 lower anterior teeth. The test formulation was compared to Crest Cavity Protection, as a control dentifrice. A total of 40 randomized test subjects began the study with 20 assigned to the control dentifrice and 20 assigned to the Tartarase groups (ten each, one brushing with Tartarase twice daily and one brushed with Tartarase and wore a dental tray filled with Tartarase for 30 min then brushed again with Tartarase, once daily). The Crest group experienced a 12% increase in calculus, in contrast to the results of both Tartarase groups that experienced a 40% reduction in calculus in 4 weeks of unsupervised at home use of the Tartarase toothpaste formulation. This proof of principle study demonstrates that a dentifrice, formulated along the lines of the Tartarase material, is capable of combating calculus accumulation using the same oral hygiene habits that are common worldwide. The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics, Inc. has developed novel model of calculus development and structure and has formulated a dentifrice (Tartarase™) using digestive enzymes as active ingredients that is shown to dissolve dental calculus in this Proof of Principle clinical trial. This investigation was designed to evaluate the safety and efficacy of a novel enzyme formulation to remove existing calculus deposits in 4 weeks, measured using the Volpe-Manhold Index (V-MI) on lingual surfaces of 6 lower anterior teeth. The test formulation was compared to Crest Cavity Protection, as a control dentifrice. A total of 40 randomized test subjects began the study with 20 assigned to the control dentifrice and 20 assigned to the Tartarase groups (ten each, one brushing with Tartarase twice daily and one brushed with Tartarase and wore a dental tray filled with Tartarase for 30 min then brushed again with Tartarase, once daily). The Crest group experienced a 12% increase in calculus, in contrast to the results of both Tartarase groups that experienced a 40% reduction in calculus in 4 weeks of unsupervised at home use of the Tartarase toothpaste formulation. This proof of principle study demonstrates that a dentifrice, formulated along the lines of the Tartarase material, is capable of combating calculus accumulation using the same oral hygiene habits that are common worldwide. This trial was registered retrospectively at clinicaltrials.gov and has the Unique Identification Number: NCT06139835, 14/11/2023. BackgroundThe dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics, Inc. has developed novel model of calculus development and structure and has formulated a dentifrice (Tartarase™) using digestive enzymes as active ingredients that is shown to dissolve dental calculus in this Proof of Principle clinical trial.MethodsThis investigation was designed to evaluate the safety and efficacy of a novel enzyme formulation to remove existing calculus deposits in 4 weeks, measured using the Volpe-Manhold Index (V-MI) on lingual surfaces of 6 lower anterior teeth. The test formulation was compared to Crest Cavity Protection, as a control dentifrice. A total of 40 randomized test subjects began the study with 20 assigned to the control dentifrice and 20 assigned to the Tartarase groups (ten each, one brushing with Tartarase twice daily and one brushed with Tartarase and wore a dental tray filled with Tartarase for 30 min then brushed again with Tartarase, once daily).ResultsThe Crest group experienced a 12% increase in calculus, in contrast to the results of both Tartarase groups that experienced a 40% reduction in calculus in 4 weeks of unsupervised at home use of the Tartarase toothpaste formulation.ConclusionsThis proof of principle study demonstrates that a dentifrice, formulated along the lines of the Tartarase material, is capable of combating calculus accumulation using the same oral hygiene habits that are common worldwide.Trial registrationThis trial was registered retrospectively at clinicaltrials.gov and has the Unique Identification Number: NCT06139835, 14/11/2023. Abstract Background The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics, Inc. has developed novel model of calculus development and structure and has formulated a dentifrice (Tartarase™) using digestive enzymes as active ingredients that is shown to dissolve dental calculus in this Proof of Principle clinical trial. Methods This investigation was designed to evaluate the safety and efficacy of a novel enzyme formulation to remove existing calculus deposits in 4 weeks, measured using the Volpe-Manhold Index (V-MI) on lingual surfaces of 6 lower anterior teeth. The test formulation was compared to Crest Cavity Protection, as a control dentifrice. A total of 40 randomized test subjects began the study with 20 assigned to the control dentifrice and 20 assigned to the Tartarase groups (ten each, one brushing with Tartarase twice daily and one brushed with Tartarase and wore a dental tray filled with Tartarase for 30 min then brushed again with Tartarase, once daily). Results The Crest group experienced a 12% increase in calculus, in contrast to the results of both Tartarase groups that experienced a 40% reduction in calculus in 4 weeks of unsupervised at home use of the Tartarase toothpaste formulation. Conclusions This proof of principle study demonstrates that a dentifrice, formulated along the lines of the Tartarase material, is capable of combating calculus accumulation using the same oral hygiene habits that are common worldwide. Trial registration This trial was registered retrospectively at clinicaltrials.gov and has the Unique Identification Number: NCT06139835, 14/11/2023. Background The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics, Inc. has developed novel model of calculus development and structure and has formulated a dentifrice (Tartarase™) using digestive enzymes as active ingredients that is shown to dissolve dental calculus in this Proof of Principle clinical trial. Methods This investigation was designed to evaluate the safety and efficacy of a novel enzyme formulation to remove existing calculus deposits in 4 weeks, measured using the Volpe-Manhold Index (V-MI) on lingual surfaces of 6 lower anterior teeth. The test formulation was compared to Crest Cavity Protection, as a control dentifrice. A total of 40 randomized test subjects began the study with 20 assigned to the control dentifrice and 20 assigned to the Tartarase groups (ten each, one brushing with Tartarase twice daily and one brushed with Tartarase and wore a dental tray filled with Tartarase for 30 min then brushed again with Tartarase, once daily). Results The Crest group experienced a 12% increase in calculus, in contrast to the results of both Tartarase groups that experienced a 40% reduction in calculus in 4 weeks of unsupervised at home use of the Tartarase toothpaste formulation. Conclusions This proof of principle study demonstrates that a dentifrice, formulated along the lines of the Tartarase material, is capable of combating calculus accumulation using the same oral hygiene habits that are common worldwide. Trial registration This trial was registered retrospectively at clinicaltrials.gov and has the Unique Identification Number: NCT06139835, 14/11/2023. The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics, Inc. has developed novel model of calculus development and structure and has formulated a dentifrice (Tartarase™) using digestive enzymes as active ingredients that is shown to dissolve dental calculus in this Proof of Principle clinical trial.BACKGROUNDThe dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics, Inc. has developed novel model of calculus development and structure and has formulated a dentifrice (Tartarase™) using digestive enzymes as active ingredients that is shown to dissolve dental calculus in this Proof of Principle clinical trial.This investigation was designed to evaluate the safety and efficacy of a novel enzyme formulation to remove existing calculus deposits in 4 weeks, measured using the Volpe-Manhold Index (V-MI) on lingual surfaces of 6 lower anterior teeth. The test formulation was compared to Crest Cavity Protection, as a control dentifrice. A total of 40 randomized test subjects began the study with 20 assigned to the control dentifrice and 20 assigned to the Tartarase groups (ten each, one brushing with Tartarase twice daily and one brushed with Tartarase and wore a dental tray filled with Tartarase for 30 min then brushed again with Tartarase, once daily).METHODSThis investigation was designed to evaluate the safety and efficacy of a novel enzyme formulation to remove existing calculus deposits in 4 weeks, measured using the Volpe-Manhold Index (V-MI) on lingual surfaces of 6 lower anterior teeth. The test formulation was compared to Crest Cavity Protection, as a control dentifrice. A total of 40 randomized test subjects began the study with 20 assigned to the control dentifrice and 20 assigned to the Tartarase groups (ten each, one brushing with Tartarase twice daily and one brushed with Tartarase and wore a dental tray filled with Tartarase for 30 min then brushed again with Tartarase, once daily).The Crest group experienced a 12% increase in calculus, in contrast to the results of both Tartarase groups that experienced a 40% reduction in calculus in 4 weeks of unsupervised at home use of the Tartarase toothpaste formulation.RESULTSThe Crest group experienced a 12% increase in calculus, in contrast to the results of both Tartarase groups that experienced a 40% reduction in calculus in 4 weeks of unsupervised at home use of the Tartarase toothpaste formulation.This proof of principle study demonstrates that a dentifrice, formulated along the lines of the Tartarase material, is capable of combating calculus accumulation using the same oral hygiene habits that are common worldwide.CONCLUSIONSThis proof of principle study demonstrates that a dentifrice, formulated along the lines of the Tartarase material, is capable of combating calculus accumulation using the same oral hygiene habits that are common worldwide.This trial was registered retrospectively at clinicaltrials.gov and has the Unique Identification Number: NCT06139835, 14/11/2023.TRIAL REGISTRATIONThis trial was registered retrospectively at clinicaltrials.gov and has the Unique Identification Number: NCT06139835, 14/11/2023. |
| ArticleNumber | 720 |
| Audience | Academic |
| Author | Milleman, Jeffery L. Mish, Barbara Schuller, Reinhard Deener, Greg Mynarcik, Dennis Milleman, Kimberly R. |
| Author_xml | – sequence: 1 givenname: Kimberly R. surname: Milleman fullname: Milleman, Kimberly R. organization: Salus Research, Inc – sequence: 2 givenname: Greg surname: Deener fullname: Deener, Greg organization: Pontis Biologics, Inc., Long Island High Technology Incubator – sequence: 3 givenname: Jeffery L. surname: Milleman fullname: Milleman, Jeffery L. organization: Salus Research, Inc – sequence: 4 givenname: Barbara surname: Mish fullname: Mish, Barbara organization: Pontis Biologics, Inc., Long Island High Technology Incubator – sequence: 5 givenname: Reinhard surname: Schuller fullname: Schuller, Reinhard organization: Reinhard Schuller Consulting – sequence: 6 givenname: Dennis surname: Mynarcik fullname: Mynarcik, Dennis email: dennis@pontisbio.com organization: Pontis Biologics, Inc., Long Island High Technology Incubator |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38909189$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UsmO1DAUjNAgZoEf4IAiceGSwVsSmwtqjVhGGokLnC3Hfulx49iNnfQsX8Bn43Q3zQxCyJa8vKqy66lOiyMfPBTFS4zOMebN24SJQLRChFWIMcGr2yfFCWYtqRpO8dGD_XFxmtIKIdxyxp4Vx5QLJDAXJ8XPRbmOIfRlnutovbZrB6X1G0ijXarRBj-XVOnDBlwJ_v5ugLIPcZjcvupLA35UrtTK6clNKZ_XIdm5-i4zWXUD8L2Mypsw2Hsw5fU0KF9qZ73NnHKMVrnnxdNeuQQv9utZ8e3jh68Xn6urL58uLxZXla5rMVZUN7UBWtcd6noAarSmpG2h6RQ2CNeMGM572taCsY4zZVgLhNY9wZS1umf0rLjc6ZqgVjJbHlS8k0FZub0IcSlVHK12IME0DTca1wIE41gLJroGtDDCdIQjkrXe77TWUzeA0bkNUblHoo8r3l7LZdhIjLGgpMZZ4c1eIYYfU-65HGzS4JzyEKYkKWox4RQhmqGv_4KuwhR97tWMEgS1JCMPqKXKDqzvQ35Yz6Jy0QresKbdfvz8H6g8DAxW55T1Nt8_Irx66PRg8XeQMoDsADqGlCL0BwhGck6r3KVV5rTKbVrlbSbRHSnN0VtC_GPpP6xfyqntkQ |
| Cites_doi | 10.1111/prd.12361 10.1111/jcpe.12450 10.1186/1472-6831-13-50 10.1016/j.adaj.2018.04.023 10.1002/cre2.559 10.1038/srep43344 10.1016/j.molmed.2014.11.004 10.3390/microorganisms10122413 10.1016/j.jdsr.2014.04.001 10.1111/eos.12425 10.4161/gmic.1.4.12778 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12903-024-04498-x |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: ProQuest Publicly Available Content url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Dentistry |
| EISSN | 1472-6831 |
| EndPage | 8 |
| ExternalDocumentID | oai_doaj_org_article_ed668dc159e9481c949b6ec9d9db2802 PMC11193251 A798646702 38909189 10_1186_s12903_024_04498_x |
| Genre | Randomized Controlled Trial Journal Article |
| GeographicLocations | Canada United States--US |
| GeographicLocations_xml | – name: Canada – name: United States--US |
| GrantInformation_xml | – fundername: Pontis Biologics, Inc. grantid: PB2022-01; PB2022-01; PB2022-01 – fundername: Pontis Biologics, Inc. grantid: PB2022-01 |
| GroupedDBID | --- 0R~ 23N 2WC 34H 53G 5GY 5VS 6J9 6PF 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABUWG ACGFO ACGFS ACPRK ADBBV ADFRT ADRAZ ADUKV AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK IAO IHR INH INR ITC IVC KQ8 LK8 M1P M48 M7P M~E O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ TR2 UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION -A0 3V. ACRMQ ADINQ ALIPV C24 CGR CUY CVF ECM EIF NPM 7QP 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c559t-3c65de355b0bfee3dcc3277e6ba1d01542d88f375944b84ad47e235f21347cf43 |
| IEDL.DBID | RSV |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001252611500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1472-6831 |
| IngestDate | Fri Oct 03 12:35:00 EDT 2025 Tue Nov 04 02:05:47 EST 2025 Sun Nov 09 10:21:11 EST 2025 Thu Oct 09 21:41:24 EDT 2025 Tue Nov 11 11:02:35 EST 2025 Tue Nov 04 18:19:08 EST 2025 Wed Feb 19 02:08:42 EST 2025 Sat Nov 29 02:35:37 EST 2025 Sat Sep 06 07:26:40 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Enzymes Volpe-Manhold Index (V-MI) Formulation Brushing Calculus Adverse Safety |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c559t-3c65de355b0bfee3dcc3277e6ba1d01542d88f375944b84ad47e235f21347cf43 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://link.springer.com/10.1186/s12903-024-04498-x |
| PMID | 38909189 |
| PQID | 3079207228 |
| PQPubID | 42535 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ed668dc159e9481c949b6ec9d9db2802 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11193251 proquest_miscellaneous_3071283003 proquest_journals_3079207228 gale_infotracmisc_A798646702 gale_infotracacademiconefile_A798646702 pubmed_primary_38909189 crossref_primary_10_1186_s12903_024_04498_x springer_journals_10_1186_s12903_024_04498_x |
| PublicationCentury | 2000 |
| PublicationDate | 2024-06-22 |
| PublicationDateYYYYMMDD | 2024-06-22 |
| PublicationDate_xml | – month: 06 year: 2024 text: 2024-06-22 day: 22 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC oral health |
| PublicationTitleAbbrev | BMC Oral Health |
| PublicationTitleAlternate | BMC Oral Health |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | 4498_CR3 H Valen (4498_CR5) 2018; 126 4498_CR1 RJ Lamont (4498_CR6) 2015; 21 P Riley (4498_CR12) 2013; 2013 PI Eke (4498_CR2) 2018; 149 SE Adams (4498_CR9) 2017; 7 AR Volpe (4498_CR14) 1930; 1965 L Winning (4498_CR4) 2015; 42 H Hayasaki (4498_CR10) 2014; 50 M Derrien (4498_CR7) 2010; 1 NS Jakubovics (4498_CR13) 2021; 86 C Jones (4498_CR15) 2013; 13 M Bertolini (4498_CR8) 2022; 10 AA Al-Hashedi (4498_CR11) 2022; 8 |
| References_xml | – volume: 2013 start-page: CD010514 issue: 12 year: 2013 ident: 4498_CR12 publication-title: Cochrane Database Syst Rev – volume: 86 start-page: 32 issue: 1 year: 2021 ident: 4498_CR13 publication-title: Periodontol 2000 doi: 10.1111/prd.12361 – ident: 4498_CR3 – volume: 1965 start-page: 292 issue: 36 year: 1930 ident: 4498_CR14 publication-title: J Periodontol – volume: 42 start-page: 799 issue: 9 year: 2015 ident: 4498_CR4 publication-title: J Clin Periodontol doi: 10.1111/jcpe.12450 – volume: 13 start-page: 50 year: 2013 ident: 4498_CR15 publication-title: BMC Oral Health doi: 10.1186/1472-6831-13-50 – volume: 149 start-page: 576 issue: 7 year: 2018 ident: 4498_CR2 publication-title: J Am Dent Assoc. doi: 10.1016/j.adaj.2018.04.023 – volume: 8 start-page: 863 issue: 4 year: 2022 ident: 4498_CR11 publication-title: Clin Exp Dent Res doi: 10.1002/cre2.559 – ident: 4498_CR1 – volume: 7 start-page: 43344 year: 2017 ident: 4498_CR9 publication-title: Sci Rep doi: 10.1038/srep43344 – volume: 21 start-page: 172 issue: 3 year: 2015 ident: 4498_CR6 publication-title: Trends Mol Med doi: 10.1016/j.molmed.2014.11.004 – volume: 10 start-page: 2413 issue: 12 year: 2022 ident: 4498_CR8 publication-title: Microorganisms doi: 10.3390/microorganisms10122413 – volume: 50 start-page: 69 year: 2014 ident: 4498_CR10 publication-title: Jpn Dent Sci Rev doi: 10.1016/j.jdsr.2014.04.001 – volume: 126 start-page: 13 issue: Suppl 1 year: 2018 ident: 4498_CR5 publication-title: Eur J Oral Sci doi: 10.1111/eos.12425 – volume: 1 start-page: 254 issue: 4 year: 2010 ident: 4498_CR7 publication-title: Gut Microbes doi: 10.4161/gmic.1.4.12778 |
| SSID | ssj0017844 |
| Score | 2.3330727 |
| Snippet | Background
The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis... The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis Biologics,... Background The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis... BackgroundThe dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare industry. Pontis... Abstract Background The dissolution of dental calculus, safely and at home, is among the more challenging issues facing the over-the-counter healthcare... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 720 |
| SubjectTerms | Adult Adverse Biofilms Brushing Calculus Cardiovascular disease Care and treatment Clinical trials Control Dental calculus Dental Calculus - prevention & control Dental caries Dental plaque Dentifrices - therapeutic use Dentistry Diabetes Diagnosis Digestive enzymes Disease prevention Enzymes Female Fluorides Health aspects Humans Hygiene Identification and classification Male Medicine Microbial mats Middle Aged Mouth diseases Oral and Maxillofacial Surgery Oral diseases Oral hygiene Proof of Concept Study Safety Teeth Toothbrushing Toothpaste Volpe-Manhold Index (V-MI) |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDLfQhIALgvFVGChISByg2ntpmqTcHh8TB5g4gLRb1CSueIK10942xv4C_mzstH1bhxAXpF7aJGoSO7Gd2D8DPLNk9JTWhzx6ZFDtOM9rH21OxpZBrJtZrVOg8Aezu2v39qpPF1J9sU9YDw_cT9w2Rq1tDCR1kYFFQqUqrzFUsYpe2h5GkrSe0Zga7g-MVWoMkbF6e8WnLXxfyU4XqrL56UQMJbT-P_fkC0LpssPkpVvTJIx2bsHNQYsUi773t-EKtptw_S17_nDytk249nG4M78DvxaCftU1gp6D8WhdLM_xNbqWi2rRdif4XWB79nMfBeuyQ2YvQU9MUZOCCMrHhSt6H729XlFLlf9A_CZI7MVuf3mGUaTUf2IMuxQpN8hd-LLz7vOb9_mQfyEPZGcc5UXQZURSSPzMN4hFDKGQxqD29Tyy7iWjtQ3RulLKW1VHZVAWZcMgcSY0qrgHG23X4gMQXimUwddNI2vVaGIEiWTGq1hKqxsvM3gxksMd9DAbLpknVrueeI6I5xLx3GkGr5li65oMkZ0-EOO4gXHcvxgng-dMb8cLmYga6iEegTrMkFhuYRi5XhuuuTWpSQswTItHjnHDBrBytHVWcmaktBk8XRdzS3Zqa7E7TnXmjL82KzK43zPYekikR5ImZ6sM7IT1JmOelrTLrwkenKQXKeXlPIOXI5ee9-vvk_rwf0zqI7gh0yrTuZRbsHF0eIyP4Wo4IfY_fJLW6G8XqEJG priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZgi4ALj_IKFGQkJA4QNet4HYcL2kIrDrCqEEi9WbE9gRU0WXbbUvoL-NnMeJ1dUgQXpFx27Shx5rM9nsc3jD3ReOgZaetSb4FItf0wrazXKR62CoCqzioVEoXfFpOJPjgo96PBbRHDKrs1MSzUvnVkI99GLJYiK4TQL2ffUqoaRd7VWELjItsgpjI5YBs7u5P99ys_QqGl7FJltNpekNWF_JYUfCFLnZ72tqPA2v_n2vzb5nQ-cPKc9zRsSnvX_3c4N9i1qI7y8RI_N9kFaDbZldcUQkRV4DbZ5XfR-X6L_RxzfEhbc7xmnY2eT9dEHW1DTRVv2hP4yqE5-3EInJTiWCKM4-VD-iVHZJDdcYG_u7CxF3inTL8DfOG4f_r2cHoGnocagrzL3-ShyMht9nFv98OrN2ks5JA6PLAcpblTIw-o2djM1gC5dy4XRQHKVkNPSpzwWtcImlJKq2XlZQEiH9XENle4WuZ32KBpG7jHuJUShLNVXYtK1goRJQBsLv1IaFVbkbBnnTzNbMnXYcI5RyuzlL5B6ZsgfXOasB0S-aoncW2HP9r5JxOnrgGvlPYO9T4gahtXytIqcKUvvRU6w0c-JcAYWhEQFa6KiQ34wsStZcYFUeCrgnpu9XriTHb95g4rJq4kC7MGSsIer5rpToqOa6A9Dn2GROSW5Qm7u0ToakiokKJKqMuE6R52e2PutzTTz4FnHLdB1O5Hw4Q972C-fq-_f9T7_x7GA3ZVhAmoUiG22OBofgwP2SV3gsCeP4oT-BczmFFW priority: 102 providerName: ProQuest |
| Title | A proof of principle investigation of a novel enzyme formulation on dental calculus deposition: a 4-week randomized human clinical trial |
| URI | https://link.springer.com/article/10.1186/s12903-024-04498-x https://www.ncbi.nlm.nih.gov/pubmed/38909189 https://www.proquest.com/docview/3079207228 https://www.proquest.com/docview/3071283003 https://pubmed.ncbi.nlm.nih.gov/PMC11193251 https://doaj.org/article/ed668dc159e9481c949b6ec9d9db2802 |
| Volume | 24 |
| WOSCitedRecordID | wos001252611500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMed Central customDbUrl: eissn: 1472-6831 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017844 issn: 1472-6831 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1472-6831 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017844 issn: 1472-6831 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1472-6831 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017844 issn: 1472-6831 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1472-6831 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017844 issn: 1472-6831 databaseCode: M7P dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1472-6831 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017844 issn: 1472-6831 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1472-6831 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017844 issn: 1472-6831 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Publicly Available Content customDbUrl: eissn: 1472-6831 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017844 issn: 1472-6831 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1472-6831 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017844 issn: 1472-6831 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgQ8ALH-MrMCojIfEAEa3j2g5vHWwCiVXV-FB5smL7AhUsmdptwP4C_mzu3KQjAx5AiiIlthXb-Z3vbN_9zNhDg5OeoXE-DQ6IVDsM0sIFk-JkSwMUZb9QMVD4tR6PzXSaT5qgsEXr7d5uScaROoq1UU8XtGJCe47kOCFzk6LluI7qzpA47r15v9o70EbKNjzmj-U6Kigy9f8-Hv-ikM46S57ZMY2KaOfq_zXhGrvSGJ58tETKdXYOqg126QU5C9F5bxvs4m6zzX6D_RhxrGFdcrwO2tV4Pjul5KgrSip4VR_DFw7Vyfd94GT-NoeBcbxCDLTkiAFaYVzgc-sg9gxLyvQrwGeOmjLU-7MTCDyeFsjbSE0ejxO5yd7tbL99_jJtjmxIPU5NDtPMq2EAtGFc35UAWfA-E1qDcsUgkLkmgjElwiOX0hlZBKlBZMOSeOW0L2V2i61VdQV3GHdSgvCuKEtRyFIhdgTgzF-GoTCqdCJhj9u_aA-WzBw2zmiMssuOttjRNna0_ZawLfrRq5zEqh1f1POPthFSC0EpEzxaeEAkNj6XuVPg85AHJ0wfP_mIYGJJ9hELvmhCGLDCxKJlR5rI7pWmnJudnCizvpvcAs02Y8bC4mibi74WwiTswSqZSpIfXAX1UcwzIMq2fpaw20tcrpqEpicafyZPmOkgttPmbko1-xQZxVHhoR0_HCTsSQvc03r9vVPv_lv2e-yyiNhXqRCbbO1wfgT32QV_jECf99h5PdXxbnpsfWt7PNnrxRWSHvnjTvDd5NXu5EMvCvtPYMdOAw |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQIwXLuNWGGAkEA8jWuu4joOEUGFMm9ZNPAypbya2T6CCJaXd_Rfwa_iNnOMmLRmCtz0g5aW10-S437nZ58LYM41OT1dbF3kLVFTbd6LMeh2hs5UAZHk7UyFRuJ_s7urBIP2wwH7WuTAUVlnLxCCofeloj3wNsZiKdiKEfjP6HlHXKDpdrVtoTGGxDafH6LJNXm-t4__7XIiN93vvNqOqq0Dk0Ho-iGKnuh5Qzdq2zQFi71wskgSUzTqeLArhtc6RglRKq2XmZQIi7uZU-ixxuYzxdy-xyyjHEwohSwYzB6-TaCnrxByt1ia0x0OnpBTqIVMdnTSUX-gR8Kcm-E0Vng_TPHdWG1Tgxo3_bfFusuuVsc17U-64xRagWGZL6xQgRT3ultnVnSq04Db70eNIVJlzvEb1CQQfzsuQlAUNZbwoj-Abh-LsdB84mfxVAzSOlw_JpRxxT7uqE_xcB8W9wjtldAzwlaN14Mv94Rl4Hjok8jo7lYcWKnfYxwtZk7tssSgLuM-4lRKEs1mei0zmCvlFANhY-q7QKreixVZr_JjRtBqJCV6cVmaKNoNoMwFt5qTF3hLEZjOpknj4ohx_NpVgMuCV0t6hVQtUuMelMrUKXOpTb4Vu4yNfEEANyTtEocuqtA18YaocZnoJFfhXCc1cacxEOeWawzU2TSUnJ2YOzBZ7OhumOyn2r4DyMMzpUJm6dtxi96YcMSMJzW00eHXaYrrBKw2amyPF8Euooo5KHn2XbqfFXtZsNX-vvy_qg3-T8YQtbe7t9E1_a3f7IbsmAvOrSIgVtngwPoRH7Io7QpCPHwfRwdmni2a3X9NzrKs |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQQYULj_IKFDASEgeIuut4HYfbQlmBKKtKPNSbFdtjWEGT1XZboL-An82Mk2ybAgeElEvWY63tfGOP7ZlvGHukcdMz0tal3gKRavthWlqvU9xs5QBlGJQqBgrv5NOp3tsrdk9F8Udv9-5KsolpIJamark196FRca22Duj0hO4fyYlCFjpFK_K8pKRBtF9_93F1j5BrKbtQmT_W6y1HkbX_97n51OJ01nHyzO1pXJQmV_6_O1fZ5dYg5eMGQdfYOag22MVtciKiPHAbbP1te_1-nf0cc2xtHTg-8-6Uns9OqDrqiopKXtVH8JVDdfxjHziZxW2SMI6PjwGYHLFBJ48H-N45jj3DmjL9BvCF4wrq6_3ZMXgeswjyLoKTxzQjN9iHycv3L16lbSqH1OGWZZlmTo08oG1jBzYAZN65TOQ5KFsOPZlxwmsdEDaFlFbL0sscRDYKxDeXuyCzm2ytqiu4zbiVEoSzZQiilEEhpgSAzaQfCa2CFQl70n1RM28YO0zc6WhlmoE2ONAmDrT5nrDn9NFXksS2HX-oF59Mq7wGvFLaO7T8gMhtXCELq8AVvvBW6AH-5WOCjKE5AXHhyja0ARtM7FpmnBMJvspJcrMnibrs-sUd6Ew7lxwYnIULMciF0Al7uCqmmuQfV0F9GGWGROU2yBJ2q8HoqktokqJRqIuE6R56e33ul1Szz5FpHBdCtO9Hw4Q97UB80q6_D-qdfxN_wNZ3tydm5_X0zV12SUQ1UKkQm2xtuTiEe-yCO0LML-5H3f4F8MRSxg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+proof+of+principle+investigation+of+a+novel+enzyme+formulation+on+dental+calculus+deposition%3A+a+4-week+randomized+human+clinical+trial&rft.jtitle=BMC+oral+health&rft.au=Milleman%2C+Kimberly+R&rft.au=Deener%2C+Greg&rft.au=Milleman%2C+Jeffery+L&rft.au=Mish%2C+Barbara&rft.date=2024-06-22&rft.eissn=1472-6831&rft.volume=24&rft.issue=1&rft.spage=720&rft_id=info:doi/10.1186%2Fs12903-024-04498-x&rft_id=info%3Apmid%2F38909189&rft.externalDocID=38909189 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1472-6831&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1472-6831&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1472-6831&client=summon |